Can anything shut down the Gold rally?
RADNOR, Pa. - Avantor, Inc. (NYSE:AVTR), a $6.7 billion revenue life sciences company with a solid financial health score according to InvestingPro, announced Friday the appointment of Gregory T. Lucier to its Board of Directors, bringing more than three decades of leadership experience in the life sciences industry.
Lucier currently serves as Executive Chairman and CEO of Corza Medical, a manufacturer of surgical technologies and medical device components. He also holds board positions at Dentsply Sirona and Maravai LifeSciences. The appointment comes as Avantor demonstrates strong market performance, with the stock gaining over 16% in the past week.
His previous executive roles include serving as Chairman and CEO of NuVasive from 2015 to 2021 and as Chairman and CEO of Life Technologies from 2003 to 2014. At Life Technologies, Lucier expanded Invitrogen to over $4 billion in sales before overseeing its sale to Thermo Fisher Scientific in 2014.
"We are excited to welcome Greg to the Avantor Board of Directors," said Jonathan Peacock, Chairman of the Avantor Board, in a press release statement. "Greg has a tremendous track record of driving growth and innovation during his more than 30-year career in the Life Sciences sector."
Lucier holds a bachelor’s degree in industrial engineering from Pennsylvania State University and an MBA from Harvard Business School. His early career included various executive leadership positions as a corporate officer at General Electric Company.
Avantor provides mission-critical products and services to customers in the life sciences and advanced technology industries, serving over 300,000 customer locations across 180 countries. The company maintains a healthy 33.25% gross profit margin and trades at an attractive P/E ratio of 13.6x. For detailed financial analysis and additional insights, investors can access the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 US stocks including Avantor.
In other recent news, Avantor, Inc. reported a miss in its second-quarter 2025 earnings and subsequently lowered its full-year guidance. This has led to RBC Capital reducing its price target for Avantor to $17, citing revenue headwinds, while maintaining an Outperform rating. Additionally, Stifel has also lowered its price target to $12 due to concerns over bioprocess growth, maintaining a Hold rating. Amid these developments, Avantor has announced that Emmanuel Ligner will assume the role of CEO on August 18, 2025, following a recommendation from the board’s nominating and governance committee. This appointment comes as part of a broader strategic initiative that includes a $400 million cost transformation program and significant debt reduction. Activist investor Engine Capital has taken a 3% stake in Avantor and is advocating for strategic changes or a potential sale to enhance shareholder value. Engine Capital suggests that Avantor could achieve a share price of $22 to $26 by the end of 2027 through these changes. These recent developments underscore the ongoing strategic shifts within Avantor as it navigates its financial challenges and leadership changes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.